Risperidone and Cytochrome P450 3A
J Clin Psychiatry 1997;58(10):450 [letter]
© Copyright 2015 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Letter to the Editor
Sir: We read with great interest the recent article by Ereshefsky on pharmacokinetics and drug interactions of the new antipsychotics. This work is timely and provides invaluable information for clinicians regarding drug interactions with atypical antipsychotics. In his discussion of cytochrome P450 3A (CYP3A) isoenzyme induction by carbamazepine, Ereshefsky relates that metabolism of certain typical and atypical antipsychotics usually increases when carbamazepine is coadministered.